Altasciences has been chosen by Virpax Pharmaceuticals to conduct a first-in-human study of Epoladerm (diclofenac epolamine) for chronic pain associated with osteoarthritis of the knee. This treatment is supplied in a pre-filled device for administration as a topical spray film.

The study will be conducted in Q2 2022 at Altasciences’ clinical pharmacology unit in Montreal, Canada.

“We look forward to working with Altasciences to accelerate the development of this analgesic treatment and provide robust data in support of the 505(b)(2) FDA approval pathway,” said Virpax’s chairman and CEO, Anthony P. Mack.

Virpax’s proprietary technology provides a pre-filled canister for the therapeutic application of a clear, fast-drying spray film that is thinner than a standard liquid bandage. This technology offers convenience and eliminates the need for messy creams or gels.

Altasciences leverages decades of experience conducting first-in-human clinical trials, a vast database of study participants, and state-of-the-art bioanalytical facilities to provide expert guidance and personalized solutions.

Ingrid Holmes, Altasciences’ vice president, global clinical operations, said, “We are proud to partner with Virpax to help move this important therapeutic further along the path to regulatory approval.”